Empowering Everyone to be part of
curing human disease.
We are empowering customers to participate in research that actually makes a difference. To be a part of curing human disease.
– Anne Wojcicki -
CEO & Co-Founder
80%+ of 23andMe customers opt-in
to participate in research.
200+ papers published about our genetic findings, thanks to millions of customers.
But it’s more than just publishing papers. Our first program is now in human clinical trials.
Data helps us move quickly.
We now have 40+ therapeutic programs.
Phase 1 Clinical Immuno-oncology CD96
Preclinical Immuno-oncology P006
A leadership team that cares.
Adam Auton is the Vice President of Human Genetics at 23andMe. Since joining 23andMe in 2015, he has led efforts to identify genetic variants associated with disease that can inform novel drug target opportunities.
Interested in joining our diverse team of ever-curious scientists, researchers, and many more who share one common goal–to make a difference in people’s lives?